The metabolic syndrome and risk factors for biliary tract cancer: A case-control study in China

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1963-1969

  Wu, Qiao ^a   He, Xiao Dong ^a   Yu, Lan ^a   Liu, Wei ^a   Tao, Lian Yuan ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Cholangiocarcinoma; Gallbladder carcinoma; Metabolic syndrome; Risk factors

Indexed keywords

ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT TUMOR; CASE CONTROL STUDY; CHINA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATIC DUCT; HUMAN; LIVER TUMOR; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

BILE DUCTS, EXTRAHEPATIC; BILIARY TRACT NEOPLASMS; CASE-CONTROL STUDIES; CHINA; CHOLANGIOCARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; RISK FACTORS;

EID: 84872679894     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1963     Document Type: Article

References (61)

1. Alvaro D, Barbaro B, Franchitto A, et al (2006). Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol, 169, 877-88.
2. Benitez S, Camacho M, Bancells C, et al (2006). Wide proinflammatory effect of electronegative low-density lipoprotein on human endothelial cells assayed by a protein array. Biochim Biophys Acta, 1761, 1014-21.
3. Ben-Menachem T(2007). Risk factors for cholangiocarcinoma. Europ J Gastroenterol Hepatol, 19, 615-7.
4. Ben Q, Cai Q, Li Z, et al (2011). The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. Eur J Cancer, 47, 248-54.
5. Cai HH, Sun YM, Bai JF, et al (2008). Relationship between the GH-IGFs axis and the proliferation of bile duct cancer cell line QBC939 in vitro. Hepatobiliary Pancreat Dis Int, 7, 76-81.
6. Cardinale V, Semeraro R, Torrice A, et al (2010). Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol, 2, 407-16.
7. El-Serag HB, Hampel H, Javadi F (2006). The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol, 4, 369-80.
8. Federico A, Morgillo F, Tuccillo C, et al (2007). Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer, 121, 2381-6.
9. Feig DI, Sowers LC, Loeb LA (1994). Reverse chemical mutagenesis: identification of the mutagenic lesions resulting from reactive oxygen species-mediated damage to DNA. Proc Natl Acad Sci USA, 91, 6609-13.
10. Feingold KR, Soued M, Adi S, et al (1990). Tumor necrosis factor-increased hepatic very-low-density lipoprotein production and increased serum triglyceride levels in diabetic rats. Diabetes, 39, 1569-74.
11. Festi D, Dormi A, Capodicasa S, et al (2008). Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project). World J Gastroenterol, 14, 5282-9.
12. Furberg AS, Veierod MB, Wilsgaard T, et al (2004). Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst, 96, 1152-60.
13. Gatto M, Bragazzi MC, Semeraro R, et al (2010). Cholangiocarcinoma: update and future perspectives. Dig Liver Dis, 42, 253-60.
14. Giovannucci E (2001). Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr, 131, S3109-20.
15. Hammarsten J, Hogstedt B (2004). Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press, 13, 47-55.
16. Hardardottir I, Grunfeld C, Feingold KR(1994). Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol, 5, 207-15.
17. Hou PC (1956). The relationship between primary carcinoma of the liver and infestation with Clonorchis sinensis. J Pathol Bacteriol, 72, 239-46.
18. Hsing AW, Gao YT, Devesa SS, et al (1998). Rising incidence of biliary tract cancers in Shanghai, China. Int J Cancer, 75, 368-70.
19. Hsing AW, Sakoda LC, Rashid A, et al (2008). Body size and the risk of biliary tract cancer: a population-based study in China. Br J Cancer, 99, 811-5.
20. Jaiswal M, LaRusso NF, Burgart LJ, et al (2000). Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res, 60, 184-90.
21. Khan SA, Toledano MB, Taylor-Robinson SD (2008). Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford), 10, 77-82.
22. Koga A, Ichimiya H, Yamaguchi K, et al (1985). Hepatolithiasis associated with cholangiocarcinoma. Possible etiologic significance. Cancer, 55, 2826-9.
23. Lee MY, Lin KD, Hsiao PJ, et al (2011). The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism, 61, 242-9.
24. Lee TY, Lee SS, Jung SW, et al (2008). Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol, 103, 1716-20.
25. Lepage C, Cottet V, Chauvenet M, et al (2011). Trends in the incidence and management of biliary tract cancer: a French population-based study. J Hepatol, 54, 306-10.
26. Liu XF, Zou SQ, Qiu FZ (2003). Pathogenesis of cholangiocarcinoma in the porta hepatis and infection of hepatitis virus. Hepatobiliary Pancreat Dis Int, 2, 285-9.
27. Matsuda T, Marugame T (2007). International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from Cancer Incidence in Five Continents Vol. VIII. Jpn J Clin Oncol, 37, 74-5.
28. Michalaki V, Koutroulis G, Syrigos K, et al (2005). Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol Cell Biochem, 268, 19-24.
29. Moerman CJ, Bueno-de-Mesquita HB (1999). The epidemiology of gallbladder cancer: lifestyle related risk factors and limited surgical possibilities for prevention. Hepatogastroenterology, 46, 1533-9.
30. Nijhawan PK, Therneau TM, Dickson ER, et al (1999). Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology, 29, 1396-8.
31. Ohshima H, Tatemichi M, Sawa T (2003). Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys, 417, 3-11.
32. Park J, Tadlock L, Gores GJ, et al (1999). Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology, 30, 1128-33.
33. Patel T (2001). Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology, 33, 1353-7.
34. Patel T (2006). Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol, 3, 33-42.
35. Perumal V, Wang J, Thuluvath P, et al (2006). Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol, 37, 1211-6.
36. Randi G, Franceschi S, La Vecchia C (2006). Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer, 118, 1591-602.
37. Rashid A, Ueki T, Gao YT, et al (2002). K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res, 8, 3156-63.
38. Reeves ME, DeMatteo RP (2000). Genes and viruses in hepatobiliary neoplasia. Semin Surg Oncol, 19, 84-93.
39. Sandoh N, Shirai Y, Hatakeyama K (1997). Incidence of anomalous union of the pancreaticobiliary ductal system in biliary cancer. Hepatogastroenterology, 44, 1580-3.
40. Seccia M, Cavina E (1989). [Risk factors and etiopathogenesis of cancer of the gallbladder]. Ann Ital Chir, 60, 163-71; discussion 172.
41. Shaib Y, El-Serag HB (2004). The epidemiology of cholangiocarcinoma. Semin Liver Dis, 24, 115-25.
42. Shaib YH, El-Serag HB, Davila JA, et al (2005). Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology, 128, 620-6.
43. Shaib YH, El-Serag HB, Nooka AK, et al (2007). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol, 102, 1016-21.
44. Shebl FM, Andreotti G, Meyer TE, et al (2011). Metabolic syndrome and insulin resistance in relation to biliary tract cancer and stone risks: a population-based study in Shanghai, China. Br J Cancer, 105, 1424-9.
45. Shebl FM, Andreotti G, Rashid A, et al (2010). Diabetes in relation to biliary tract cancer and stones: a population-based study in Shanghai, China. Br J Cancer, 103, 115-9.
46. Shi JS, Zhou LS, Han Y, et al (2004). Expression of tumor necrosis factor and its receptor in gallstone and gallbladder carcinoma tissue. Hepatobiliary Pancreat Dis Int, 3, 448-52.
47. Suzuki H, Li Y, Dong X, et al (2008). Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev, 17, 3467-73.
48. Tang ZY, Guo EQ, Yan HC, et al (2007). Risk factors for infectious morbidity in gallbladder cancer patients treated surgically. Hepatogastroenterology, 54, 22-7.
49. Tao LY, He XD, Qu Q, et al (2010). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a case-control study in China. Liver Int, 30, 215-21.
50. Tomimatsu M, Ishiguro N, Taniai M, et al (1993). Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer, 72, 683-8.
51. Tyson GL, El-Serag HB(2011). Risk factors of cholangiocarcinoma. Hepatology, 54, 173-84
52. Wells BJ, Mainous AG, 3rd, et al (2005) Iron, cholesterol, and the risk of cancer in an 18-year cohort. Asian Pac J Cancer Prev, 6, 505-9.
53. Welzel TM, Graubard BI, El-Serag HB, et al (2007) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol, 5, 1221-8.
54. Welzel TM, McGlynn KA, Hsing AW, et al (2006). Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst, 98, 873-5.
55. Welzel TM, Mellemkjaer L, Gloria G, et al (2007). Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer, 120, 638-41.
56. West J, Wood H, Logan RF, et al (2006). Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer, 94, 1751-8.
57. Wijaya I, Abdullah M (2011). Diagnosis and treatment update: cholangiocarcinoma. Acta Med Indones, 43, 212-5.
58. Yamamoto S, Kubo S, Hai S, et al (2004). Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci, 95, 592-5.
59. Zhou HB, Wang H, Zhou DX, et al (2010). Etiological and clinicopathologic characteristics of intrahepatic cholangiocarcinoma in young patients. World J Gastroenterol, 16, 881-5.
60. Zhou YM, Yin ZF, Yang JM, et al (2008). Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol, 14, 632-5.
61. Zou S, Zhang L (2000). Relative risk factors analysis of 3,922 cases of gallbladder cancer. Zhonghua Wai Ke Za Zhi, 38, 805-8.